Prevalence in Iron deficiency Acute Heart Faliure
Recruiting
- Conditions
- heart failure, iron deficiency
- Registration Number
- NL-OMON28189
- Lead Sponsor
- Maastricht University Medical Centre ( MUMC)Prof Dr Brunner
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 1000
Inclusion Criteria
Age> 18 years
Admission with an episode of acute heart failure
Exclusion Criteria
-History of erythropoietin stimulating agent, IV iron therapy, and/or blood transfusion within 3 months prior to hospitalisation.
-Oral iron therapy at any doses in 4 weeks prior to hospitalization or iron containing multivitamins irrespectively of the dose of iron.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method This study aims to analyse the prevalence of iron deficiency (ID) in patients with an episode of acute heart failure at different time points (t0 = within 24(+12h) hours of admission due to acute decompensated heart failure, t1 = after stabilisation and within 0-2 days prior to discharge, t2 = 6 weeks after discharge (+- 2 weeks, but never earlier than 4 weeks after discharge).<br /><br><br /><br>Iron deficiency is defined as serum ferritin <100µg/l or serum ferritin =100-299µg/l and transferrin saturation <20%.<br>
- Secondary Outcome Measures
Name Time Method To determine at what time point screening for ID is reliable after a patient is hospitalized due to an acute episode (guidance for cardiologists).<br /><br>To analyse the prevalence of ID in subgroups (female, LVEF, NYHA, co-morbidities (hypertension, diabetes mellitus, COPD/asthma, CVA/TIA, cancer, anaemia, systemic inflammatory disorders, valve disease, atrial fibrillation), eGFR and CRP and anemia).<br /><br><br /><br>For possible later analyses, left-over of already drawn serum may be stored (at discretion of the investigators, until further notice in MUMC Maastricht, Zuyderland Hospital Heerlen and Amphia hospital Breda only). Such analyses might include measurement of hepcidine or soluble transferrin-receptor, among other biomarkers, to better define the role of iron deficiency in the acute setting of HF. This may also give insight if measurements of ferritin provide reliable results or if definition of ID should be different in the acute setting.<br>